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Abstract: Receptor targeted nuclear imaging directed against molecular markers overexpressed on
breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets
such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor
2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being
investigated for this purpose. Expression of these targets is BC subtype dependent and information
that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers,
e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the
studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of
imaging studies are summarized and (potential) purposes of lesion visualization by targeting these
molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target
expression can vary per subtype, but also during disease progression or under influence of treatment,
radiotracers for selected imaging purposes should be chosen carefully.
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1. Introduction
Breast cancer (BC) is the most common cancer in women worldwide. In 2012, 167 million new
BC cases were diagnosed and 522,000 people died of the disease [1]. BC is highly heterogenic and
comprises of multiple histological subtypes e.g., luminal A, luminal B, human epidermal growth factor
2 (HER2)-driven, and basal-like tumors [2]. These histological subtypes are characterized by distinctive
molecular patterns that play an important role in treatment and prognosis of the disease. The most
important molecular tumor characteristics include estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2) expression [2].
Our knowledge of BC has greatly expanded over the past years leading to new diagnostic and
therapeutic methods, which positively influenced the mortality rate of the disease. The prognosis
of metastatic BC is still poor, the estimated five-year survival being only 26% [3], and therefore new
imaging and therapeutic methods are needed. Although BC is finally diagnosed by histology, imaging
methods are indispensable for detection of the disease. Mammography is used for nationwide breast
screening, in some cases supplemented with magnetic resonance imaging (MRI) or ultrasound. These
methods are suited for screening purposes and detection of abnormal breast lesions but do not provide
information on molecular characteristics such as biomarker expression. Imaging techniques that can
provide such information can have added value, especially in highly heterogeneous cancer types.
To fulfill this purpose, target-mediated nuclear imaging of BC is being investigated.
In nuclear medicine, such target-mediated imaging is successfully applied for imaging of, e.g.,
neuroendocrine tumors [4,5]. This approach uses the molecular expression pattern of tumors for
targeting. Molecules (e.g., receptors, transporters, and enzymes) overexpressed on cancer cells can be
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targeted with synthesized target ligands (e.g., peptide analogs, antibodies, affibodies, and nanobodies)
that bind to the target with high affinity and specificity (Figure 1A).
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Figure 1. (A) Schematic overview of receptor targeted nuclear imaging. Ligands that can bind
their targets overexpressed on breast cancer (BC) cells can be coupled to a chelator, often via a
linker. The chelator enables labeling with radionuclides such as 68Ga and 111In that can be applied
for imaging purposes; (B,C) dra ing of the principles of radionuclides for single-photon emission
computed to ography (SPECT) and positron emission tomography (PET) imaging. For S CT
i ing, γ-photons from r dionuclides such as 111In re captured by detectors at multiple positions
around the longitudinal axis of the p tient. For PET imaging positrons emitted from a radionuclide
such as 68Ga interact with electr ns which resu ts in the production of 2 γ-photons. These photon are
picked up by opposing detec rs install d in a ring-like pattern.
Depending on the radionuclide that these targeting agents are conjugated with, single-photon
emission computed tomography (SPECT) or positron emission tomography (PET) can be performed.
SPECT and PET are functional, highly sensitive nuclear imaging methods based on the detection of
γ-photons directly or indirectly derived from γ-emitting (e.g., 111In) or positron-emitting (e.g., 68Ga)
radionuclides, respectively (Figure 1B,C). Combining SPECT or PET with computed tomography (CT)
or MRI provides functional imaging information in combination with high resolution imaging of
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anatomical structures [6,7]. In the review by Pattion et al. [8] and the paper by Ziegler et al. [9] the
mechanisms of SPECT and PET imaging are described in more detail. With respect to BC imaging,
dedicated SPECT and PET imaging devices have been developed that have a higher resolution and
thus better diagnostic accuracy than whole body SPECT and PET systems [10,11].
Targeted nuclear imaging may potentially be used for disease characterization, disease
visualization (e.g., preoperative scanning, disease staging by visualization of regional and distant
metastases and/or detection of relapse) and in some cases to predict outcome of therapy and to
monitor/evaluate treatment response. For screening purposes, however, the use of targeted nuclear
imaging might be less suited since its success rate is dependent on sufficient target expression, and
because of the relatively high costs and the radiation burden associated with this method.
In the past years a number of molecular targets for receptor targeted nuclear imaging of BC have
been identified and are currently under investigation: hormone receptors, HER2, the somatostatin
receptor (SSTR), the gastrin releasing peptide receptor (GRPR), folate receptor (FR), C-X-C chemokine
receptor type 4 (CXCR4), neuropeptide Y receptor Y1 (NPY1R), and vasoactive intestinal polypeptide
receptor 1 (VIP-R1). In this review we describe these targets and discuss ongoing investigations and
the prospects of BC receptor targeted nuclear imaging.
This review focuses on the molecular targets mentioned above. Other radiotracers
under investigation for nuclear imaging of BC including radiotracers that accumulate in cells
due to (over)expression of functional transporters or higher metabolism in BC cells (e.g.,
18F-fluorodeoxyglucose (FDG)) are beyond the scope of this review.
2. Targeting of Hormone Receptors for Nuclear Imaging
The ER is not only interesting for therapeutic targeting options, but also for imaging. 18F-FES, a
fluorinated estradiol [12], is the most extensively studied ER-targeting PET radioligand in clinical trials.
Studies have focused on the potential of ER-mediated nuclear imaging for visualization of ER-positive
primary and metastatic BC lesions as well as the ability of the radioligand to predict response to
anti-estrogen treatment. Five clinical studies reported on sensitivity and specificity of the radiotracer
for tumor visualization; 69%–100% and 80%–100%, respectively [13–17]. Furthermore, 18F-FES imaging
was used to predict response to anti-estrogen treatment prior to and in early phases of therapy. High
uptake of 18F-FES prior to treatment indicates the presence of ER, which is necessary for a positive
therapy response, while a decrease of 18F-FES uptake in early phases of treatment is an indication of
successful treatment. Figure 2A shows an example of the use of 18F-FES for predicting therapy response
in BC patients. Up to now, positive and negative predictive values of 65% and 88%, respectively,
were reported for pre-therapy scanning in relation to anti-estrogen treatment [18–21]. Since 18F-FDG
(which reflects glucose metabolism) is the most widely used PET tracer for evaluation of treatment
response [22,23], He et al. [24] compared the use of 18F-FES and 18F-FDG in a preclinical setting and
reported that 18F-FES PET/CT was superior to 18F-FDG for predicting response to endocrine therapy.
Following the above-mentioned positive results, a substantial number of clinical trials using 18F-FES
for BC imaging have started and are still ongoing.
Based on current findings, 18F-FES could be useful for disease characterization by determining
ER expression of BC lesions (offering a less invasive method than immunostaining on biopsy material),
disease staging, and the use of the radiotracer to predict and monitor therapy response.
Because expression of the PR is an estrogen-regulated process, the primary focus was on the
development of ER-targeted radiotracers. However, ER-targeting radiotracers are not always efficient
in patients treated with anti-estrogens since these molecules bind to the ER as well, rendering the
receptor unavailable for radiotracer binding, such as interim monitoring of treatment efficacy. In this
case, PR-targeted radiotracers might be useful. Furthermore, similar to ER status, PR-targeting
radiotracers offer a less invasive method for determining PR status of breast lesions. A number
of PR-targeting radiotracers have been synthesized and investigated in preclinical and clinical
studies [25,26]. The most successful PR-targeted radiotracer, 18F-FFNP, was used in a clinical pilot
Int. J. Mol. Sci. 2017, 18, 260 4 of 18
study successfully identifying 15/16 PR-positive BCs [27]. Figure 2B shows an example of 18F-FFNP
PET images in a PR-positive and a PR-negative BC patient. Previous research reported a decrease
in PR expression after successful anti-estrogen treatment as a result of inhibition of ER-activated
pathways [28] and preclinical studies investigating the potential of 18F-FFNP PET imaging to predict
response to anti-estrogen treatment have been performed with promising results [29,30].
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Figure 2. Examples of images using the estrogen receptor (ER)-targeted radiotracer 18F-FES (A);
progesterone receptor (PR)-targeted radiotracer 18F-FFNP (B) and the human epidermal growth
factor receptor 2 (HER2)-targeted radiotracer 64Cu-DOTA-trastuzumab obtained in breast cancer (BC)
patients. Images are adapted from Gemignani et al. [17], Dehdashti et al. [27] and Tamura et al. [31],
respectively. (A) 18F-FES PET images of an ER-positive and an ER-negative BC lesion. The
ER-positive BC lesion visualized by 18F-FES P T corresponds with a 2–3 cm lesion seen on CT
and is confirmed on the 18F-FES PET/CT images. The ER-negative BC lesion is v sualized on
CT and by 18F-FDG PET but shows no 18F-FES uptake. This research was originally published
in JNM. Gemignani et al. Feasibility and predictability of perioperative PET and estrogen
receptor ligand in patients with invasive BC. J. Nucl. Med. 2013, 54, 1697–1702. © by the
Society of Nuclear Medicine and Molecular Imaging, Inc. (Ann Arbor, MI, USA); (B) 18F-FFNP
PET images in a patient with PR-positive and PR-negative BC. This research was originally
published in JNM. Dehdashti et al. Assessment of progesterone receptors in breast carcinoma by
PET with 21-18f-fluoro-16α,17α-[(r)-(1′-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.
J. Nucl. Med. 2012, 53, 363–370. © by the Society of Nuclear Medicine and Molecular Imaging,
Inc. (C) Examples of HER2-targeted imaging. In part I 64Cu-DOTA-trastuzumab PET images of a
HER2-positive primary BC is shown. Red areas show high tracer uptake in blood vessels. Part II shows
images of HER2-positive metastatic brain lesions identified by 64Cu-DOTA-trastuzumab PET imaging.
Significant tracer uptake values were found in areas corresponding to brain metastatic lesions detected
on MRI. Images in part I and II are from different patients. This research was originally published
in JNM. Tamura et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive BC. J.
Nucl. Med. 2013, 4, 1869–1875. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. Red
arrows indicate cancer lesions in the images. SUV: standardized uptake value.
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To date, clinical data on PR-targeted nuclear imaging is limited, but the reported findings indicate
that the potential application of PR radioligands lies in disease characterization by determination of
PR expression and therapy assessment after endocrine treatment.
3. Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Imaging
Similar to hormone receptors, HER2 expression in BC is not only of interest for therapeutic
interventions but also for imaging. HER2-targeted nuclear imaging has been tested in preclinical and
clinical studies using both radiolabeled monoclonal antibodies, radiolabeled affibodies, radiolabeled
nanobodies, and radiolabeled antibody fragments. Monoclonal antibodies used for therapy of
HER2-expressing BCs were radiolabeled with different radionuclides enabling both SPECT and
PET imaging. Following positive results from preclinical studies, radiolabeled trastuzumab was
investigated in clinical studies for its ability to visualize HER2-positive BC lesions [31–37]. Figure 2C
shows an example of PET images acquired after injecting HER2-positive BC patients with radiolabeled
trastuzumab. The main purpose of studying HER2-targeted nuclear imaging was to predict response
to treatment with trastuzumab as well as other types of treatment, and to predict trastuzumab-related
toxicity. The results of clinical studies were variable, limiting factors being poor visualization of liver
metastases due to high background uptake in the liver and suboptimal imaging of HER2-positive
lesions if no unlabeled trastuzumab was pre-administered. Remarkably, two studies demonstrated
that 64Cu-Trastuzumab was able to detect HER2-positive breast lesions that could not be detected
by 18F-FDG PET [31,34]. Furthermore, treatment of HER2-positive BC patients with a combination
of trastuzumab and paclitaxel or a heat shock protein 90 inhibitor NVP-AUY922 led to a decrease in
uptake of radiolabeled trastuzumab, indicating that the radiotracer can be used to assess response to
these types of treatment [35,36]. In a recent study by Gebhart et al. [38] the ability of 89Zr-trastuzumab
imaging to predict response to treatment with trastuzumab emtasine was evaluated in 56 patients.
The authors reported that HER2-targeted imaging combined with early metabolic response assessment
by 18F-FDG PET predicted response to trastuzumab emtasine treatment and discriminated between
patients that will or will not benefit from this type of therapy.
In contrast to antibodies, the smaller affibody molecules have relatively fast uptake and clearance
rates, resulting in a lower radiation burden for patients and offering the opportunity to scan patients
at earlier time points after administration of the radiotracer. Two clinical studies have been performed
evaluating the use of radiolabeled HER2-targeting affibodies in patients, which resulted in successful
imaging of HER2-positive BC lesions [39,40]. However, similar to the results with radiolabeled
trastuzumab, imaging of liver metastases was difficult because of high physiological uptake in the liver.
Additionally, radiolabeled HER2-targeting nanobodies that can be labeled with different radionuclides
(e.g., 18F, 68Ga, and 99mTc) were synthesized and applied for HER2 visualization [41–43]. The majority
of these nanobodies are still under investigation in a preclinical setting, but a recent clinical study by
Keyaerts and Xavier et al. [44] reported on the use of 68Ga-HER2-Nanobody in BC patients. Although
not the primary goal of the study, both primary and metastatic BC lesions were successfully visualized.
Furthermore, biodistribution was favorable and no toxicity was reported. In addition, radiolabeled
HER2 antibody fragments were synthesized and tested preclinically as well as clinically. Although
preclinical studies were successful [45–49], only a few clinical studies have been reported and results
were disappointing since radiotracer uptake in tumors was absent or low [50,51]. Also, radiolabeled
HER2-targeting RNA aptamers were synthesized for targeting HER2-positive BC lesions [52]. These
studies are still in a preclinical setting and their advantage to HER2-targeting antibodies, affibodies,
and nanobodies remains to be established.
Current findings indicate that HER2-targeted imaging could be applied for disease
characterization by determination of HER2 expression of breast tumors, disease staging and to monitor
therapy responses.
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4. Somatostatin Receptor (SSTR)-Mediated BC Imaging
Receptor-mediated nuclear imaging is successfully used in neuroendocrine tumor patients by
targeting SSTRs overexpressed on neuroendocrine tumor cells using SSTR-binding radioligands.
Next to neuroendocrine tumors, SSTR expression has also been reported on BC cells [53,54]. Since
radiolabeled peptide analogs targeting these receptors were available, several preclinical and clinical
studies have been performed targeting these receptors for imaging purposes. In the preclinical
study by Chereau et al. [55], 68Ga-DOTA-TOC imaging was compared to 18F-FDG PET in a BC
xenograft mouse model resulting in two times higher uptake of 68Ga-DOTA-TOC compared to 18F-FDG.
Concerning clinical investigations, in our previous review we discussed earlier clinical studies [56–66]
on SSTR-mediated imaging, showing very variable sensitivities and specificities ranging from
36%–100% and 22%–100%, respectively [67]. Figure 3A shows an example of SSTR-mediated imaging in
BC patients. Limiting factors for successful BC targeting were low and heterogeneous SSTR expression,
appropriate patient selection, the use of radiolabeled peptide analogs with suboptimal receptor affinity
and imaging equipment with low spatial resolution. For successful receptor-mediated imaging the
expression of the target should be sufficiently high. Since low and heterogeneous SSTR expression was
reported as a limiting factor for successful BC imaging, the question is whether SSTR is a suitable target
for receptor targeted nuclear BC imaging. However, another limiting factor of the previous studies
was non-appropriate patient selection. Since BC is a very heterogeneous disease, SSTR expression
between BC subtypes may vary. We and others showed higher SSTR expression in ER-positive BC
compared to ER-negative BC, identifying ER-positive BC subtypes as the most suitable subtypes for
SSTR-mediated imaging [68–71]. If we only focus on these BC subtypes, which account for the majority
of the breast tumors, SSTR-mediated BC imaging might be more successful. Furthermore, we studied
SSTR mRNA expression of primary BCs vs. SSTR mRNA expression of regional and distant metastases
and demonstrated that there was no significant difference in SSTR mRNA expression levels of primary
tumors and corresponding regional lymph node metastases as well as lung and brain metastases [72].
Previous studies have been performed with radiolabeled octreotide, which has a lower SSTR affinity
compared to the currently used radiolabeled somatostatin analogs, including Tyr3-octreotate [73].
In addition, lower spatial resolution planar imaging was used in earlier studies in comparison
to currently available whole body and dedicated SPECT and PET techniques [6,10,11]. Another
noteworthy recent development is the application of SSTR antagonists that have shown to be superior
to SSTR agonists for neuroendocrine tumor targeting [74–78]. This enhanced tumor targeting
of SSTR antagonists was explained by the ability of receptor antagonists to bind more binding
sites/receptors than receptor agonists [78]. Since SSTR expression in BC was reported to be low
and heterogeneous, the use of antagonists is promising in this respect. Cescato et al. [77] reported
11 ± 4 times higher binding of an SSTR antagonist, 177Lu-DOTA-BASS, vs. the clinically used
SSTR agonist 177Lu-DOTA-Tyr3-octreotate in seven human BC specimens. We recently reported
on enhanced binding of the radiolabeled SSTR antagonist DOTA-JR11 vs. the radiolabeled SSTR
agonist DOTA-Tyr3-octreotate in 40 BC specimens as well as superior imaging of a patient-derived BC
xenograft mouse model post injection of the radiolabeled receptor agonist vs. the antagonist [79].
Thus, previous studies on SSTR-mediated imaging in BC performed under suboptimal conditions
were not convincing, but with recent improvements as mentioned above, the outcome might change.
Additional studies that benefit from these recent developments are needed to investigate the true
potential of SSTR-mediated BC imaging. Based on previous studies, we speculate that the potential for
SSTR-mediated imaging lies in disease staging and disease monitoring.
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Figure 3. Examples of somatostatin receptor (SSTR)- (A) and gastrin releasing peptide receptor
(GRPR)- (B) mediated breast cancer (BC) imaging. Images are adapted from studies by Wang et al. [64]
and Maina and Bergsma et al. [80], respectively. (A) 99mTc-octreotide (a SSTR-targeting radiotracer)
scintigraphy identifying SSTR-positive BC tumors. SSTR2 and SSTR5 expression on cancer cells was
demonstrated by immunohistochemistry stainings. This research was reprinted from Wang et al.
The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and
correlates with expression of SSTR. Nucl. Med. Biol. 2008, 35, 665–671. Copyright, with permission
from Elsevier [64]; (B) 68Ga-SB3 scan in a BC patient, demonstrating GRPR-positive bone etastasis
in the skull: frontal bone on the left side (part II, SUVmax 2.4) and bone marrow metastasis in the
right proxi al femur (part III, arrow, SUVmax 7.8). Part I MIP; part II fused axial PET/CT image and
part III fused coronal PET/CT image. SUVmax: maximum standardized uptake value. This research
was originally published in Maina and Bergsma et al. Preclinical a first clinical experience with
the gastri -releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. Eur. J. Nucl. Med. Mol.
Imaging 2015, 43, 964–973 [80]; © Sprin er-Velag Berlin Heidelberg 2015, with permission of Springer.
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5. Gastrin Releasing Peptide Receptor (GRPR)-Mediated BC Imaging
The GRPR is a G-protein coupled receptor that is overexpressed on a high percentage of BCs.
According to literature, 62%–96% of primary BCs express GRPR [81–84]. Over the past years, multiple
GRPR-targeting radioligands have been described to target GRPR-expressing cancers. Although
the majority of these were studied in prostate cancer, these studies expanded our knowledge on
preferential radioligand properties and uptake in other/background organs. One example is the
preference for radiolabeled GRPR antagonist instead of agonists for tumor targeting, since it is
similar to what was observed for SSTR radioligands, superior binding of GRPR antagonists vs.
agonists was reported [85]. Several preclinical studies have been performed demonstrating successful
GRPR-mediated nuclear imaging using SPECT and PET in BC mouse models [84,86,87]. In the study
by Prignon et al. [86], GRPR-mediated imaging was compared to 18F-FDG PET for tumor visualization
and disease monitoring after endocrine therapy, resulting in a significant decrease in uptake of the
GRPR radiotracer, 68Ga-AMBA, in treated and non-treated animals while no significant difference in
18F-FDG uptake between the treated and non-treated group was observed. Also, we reported that
high GRPR mRNA expression levels were associated with improved progression free survival after
first line tamoxifen (Nolvadex) treatment, indicating that GRPR expression has predictive value for
response to tamoxifen treatment [68]. In the same study, we reported on higher GRPR expression in
ER-positive tumors, identifying specific BC patients suited for the application of radiotracers targeting
this receptor. Furthermore, we recently reported that BC metastases from GRPR-positive primary
BCs also express GRPR, indicating that this imaging method can be applied in both primary and
metastatic disease [72]. Although results obtained from preclinical studies are promising, to date
only a few clinical studies have been performed on GRPR-mediated nuclear BC imaging. In a study
by Maina et al. [80], four out of eight breast tumors were successfully visualized in patients with
advanced disease using 68Ga-SB3, a radiolabeled GRPR antagonist. Scan outcomes were not related to
ER expression in this study. Stoykow et al. [88] showed successful imaging in 13 out of 18 patients with
another 68Ga labeled GRPR-antagonist, 68Ga-RM2. Positive imaging results were correlated with ER
expression in accordance with our findings [68], confirming the potential of GRPR-mediated imaging
in ER-positive patients. A 68Ga-SB3 PET image from the study by Maina and Bergsma et al. [88] is
presented in Figure 3B. Although more clinical studies on the application of GRPR radioligands for BC
imaging are needed, current findings suggest that GRPR-targeted imaging might be used successfully
for disease staging and therapy evaluation in ER-positive patients.
6. Other Targets
Next to the above-mentioned targets there are some other interesting targets that are not
extensively studied in BC (yet). FR-targeting radiotracers have been applied for BC imaging.
Overexpression of the FR was associated with basal-like BCs [89]. In a clinical study, successful
SPECT imaging using a 99mTc labeled folate tracer was performed in three out of six BC patients [90].
Radiotracers targeting folate receptors are currently in clinical trials mainly focusing on targeting of
ovarian cancer.
High expression of CXCR4 and its association with invasive disease was reported in primary and
metastatic BC cells [91]. Radiotracers targeting this receptor for imaging purposes were investigated in
BC in a few preclinical studies and one clinical study [92–94]. The result of the clinical study using the
CXCR4 radiotracer 68Ga-pentixafor was disappointing and 18F-FDG seems superior to 68Ga-pentixafor
for BC imaging. However, only few BC patients were included in this study and larger clinical studies
are needed to accurately determine the value of CXCR4-mediated BC imaging. Since CXCR4 mRNA
expression was associated with ER-negative tumors [68], successful targeting would offer new imaging
opportunities for this patient group.
NPY1R expression has been reported on 85% of breast tumors and radiotracers for BC targeting
have been synthesized [95–98]. Highest expression of the receptors was reported on triple negative
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BCs [99]. Up to date, proof of successful imaging using these radiotracers is very scarce, but the
available data appear promising.
Furthermore, overexpression of VIP-R on BC cells was reported in multiple studies and
radiotracers targeting these receptors were synthesized [100,101]. One preclinical and one clinical
study described the use of radiolabeled VIP-R radiotracers (18F-dVIP and 64Cu-TP3805, respectively)
for imaging purposes in BC patients [102,103]. In the clinical study by Thakur et al. [103] 20 out of 20
BCs were successfully imaged. The authors hypothesize that VIP-R type 1-mediated imaging can be
used for early and accurate detection of BC because it is overexpressed on all BC cells in early phases
of the disease. However, the high uptake of VIP-R type 1 targeted radiotracers in the lungs reported in
studies performed in other cancer types should be kept in mind [104].
7. Future Outlooks
With the different targets discussed above being explored and available for receptor-mediated
nuclear imaging of BC, several questions remain. How can receptor targeted nuclear imaging improve
the care of BC patients and what is the best target for receptor targeted nuclear BC imaging?
One target does unfortunately not suit all BCs since this tumor type is very heterogeneous.
Figures 4 and 5 show an overview of the targets discussed in this review and the clinical setting in
which radiotracers targeting these receptors can (potentially) be applied. Of the targets currently
under investigation for receptor targeted nuclear imaging of BC, SSTR, GRPR, ER, PR, and NPY1R are
best suited for ER-positive luminal A and luminal B BCs, since these targets are the only ones or the
ones with the highest expression in these BC subtypes. Both ER- and PR-targeted radiotracers, but
especially ER-targeted radiotracers, are currently studied in clinical trials. These radiotracers can be
used for determining ER or PR expression of primary tumors and metastases as well as for evaluation
of treatment response to ER-targeted therapy. However, the majority of ER-positive BCs acquire
resistance against anti-estrogen treatment and in some cases this is due to loss of ER expression [105].
ER status of primary BCs and corresponding metastases may vary (over time) and so visualization
of metastases of ER-positive primary tumors is not feasible in all cases [106]. ER- and PR-targeted
imaging to determine receptor expression is less invasive than immunostaining on biopsy material as
is done in clinical practice. Furthermore, ER- and PR-targeted nuclear imaging comprises visualization
of the complete tumor lesion, while biopsy material is limited and not always representative for the
(heterogeneous) tumor. However, determining hormone receptor expression with nuclear imaging
would involve scanning patients several times with (different) radiotracers, which causes a significant
radiation burden to the patient that has to be kept in mind. The application of radiotracers to determine
hormone receptor status would therefore especially be beneficial for tumors that cannot be biopsied
due to an inconvenient location. In cases where ER- and/or PR-targeted imaging cannot be applied,
SSTR- and GRPR-mediated imaging, although not studied as widely as ER- and PR-mediated imaging,
may be beneficial for imaging of ER-positive primary and metastatic BC lesions. GRPR-targeting is
preferred because the receptor is expressed more frequently and at higher density [81]. Nevertheless,
both SSTR- and GRPR-mediated imaging can be beneficial in ER-positive tumors that lose ER
expression in the course of the disease. For this to be successful the relation between SSTR2, GRPR,
and ER needs to be investigated to make sure that loss of ER expression does not influence GRPR
expression. Furthermore, even though SSTR and GRPR expression is higher in ER-positive tumors,
ER-negative tumors may also express the receptor and thus radiotracers targeting these receptors might
also be applied in other patient groups. NPY1R expression was also associated with ER-positive BC’s.
To date, NPY1R-targeted BC imaging has only been performed in a limited number of studies and more
studies are needed to determine the added value of NPY1R in comparison to the above-mentioned
targets for imaging of ER-positive BCs.
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Figure 5. An overview of targets discussed in this review and the breast cancer subtype with
highest expression thereof. ER: estrogen receptor, PR: progesterone receptor, SSTR: somatostatin
receptor, GRPR: gastrin releasing peptide receptor, NPY1R: Neuropeptide Y receptor Y1, HER2: human
epidermal factor receptor 2, CXCR4: C-X-C chemokine receptor type 4, FR: folate receptor, and VIP-R1:
Vasoactive intestinal polypeptide receptor 1. Details on histological and molecular profiles are derived
from [107].
HER2-targeted BC imaging can be applied in HER2-positive BCs which account for approximately
15% of the BC population [105]. As previously mentioned, this approach can be used to determine
HER2 expression and to select patients for therapy and to monitor response to treatme t influencing
HER2 expression. Similar to ER and PR radiotracers, deter ining HER2 expression with nuclear
imaging can especially be beneficial in cases where biopsies cannot be obtained. Furthermore, as is
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the case for ER and PR, HER2 expression of primary tumors and metastases may change during the
course of the disease [107].
CXCR4 and FR targeted nuclear imaging might be beneficial for basal-like tumors, the BC subtype
with the worse prognosis [105]. CXCR4-mediated imaging in BC has not been successful up to date
which might be caused by limited CXCR4 expression at the cell surface (necessary for radiotracer
binding) or high CXCR4 expression in cancer stem cells of which only limited numbers are available in
different BC subtypes [94]. Furthermore, high FR expression was also associated with basal-like tumors.
Data on FR-targeting in BC is very limited, hampering discussion on the value of this radiotracer.
VIP-R1 is expressed on all BCs and thus radiotracers targeting VIP-R1 might be interesting for all
BC subtypes. However, VIP-R1 is only expressed in early stage disease limiting the use of this tracer in
advanced BC.
For the future, a noteworthy option might be the combination of radiotracers directed against
different targets, the so called multi-target or “cocktail” approach, with the purpose of enhancing
BC visualization. Reubi et al. [82] studied expression of SSTR, GRPR, VIPR-1, and NPY1R in
human BC specimens and reported that 60% of the tumors expressed at least two of the targets.
In this study, GRPR, NPY1R or both were expressed in almost all (93%) investigated BCs. Studies
synthesizing and preclinically testing a hetero-bivalent dual target probe for GRPR and NPY1R were
performed [108]. Next to these studies, other preclinical studies have investigated the multi-targeting
approach [109–111], but to date this was not tested in a clinical setting. A disadvantage of this approach
might be enhanced or more extensive uptake in healthy organs which naturally express these targets.
In addition to disease visualization, disease staging and evaluation of therapy response, another
benefit of receptor targeted nuclear imaging is the use of radioligands for both imaging and therapy,
following the so-called theranostic approach. Most of these radioligands can be labeled with imaging
radionuclides (γ- or positron-emitters) as well as therapeutic radionuclides (β- or α-emitters), enabling
the use of the same tracer for both imaging and therapy. This is especially interesting for treatment of
advanced disease, since distant metastases are often not accessible for resection and most systemic
agents are accompanied by severe side effects [3].
Furthermore, the use of dual labeled tracers that are labeled with both radionuclides and optical
dyes are interesting for image-guided surgery. This can benefit surgical resection of tumors by offering
preoperative imaging (SPECT or PET), intraoperative guidance (by making use of γ-probes detecting
the radioactive signal to give an approximate tumor location), and fine guidance and tumor delineation
(by detection of the optical signal), ultimately improving the success-rate of tumor resection.
8. Conclusions
Overall, receptor targeted nuclear imaging for BC imaging is promising and has the potential to
improve BC care. There is not one appropriate target for all BCs, and thus a personalized approach
should be applied. Depending on the BC subtype and the question of the physician, the appropriate
target should be selected carefully (either by biopsy or imaging, depending on the availability of
biopsy material). More studies are needed to directly compare the value of tracers targeting different
receptors in specific patient groups—for example GRPR, SSTR, ER, PR, and NPY1R targeted imaging
in ER-positive BCs and clinical studiescomparing their added value to currently available 18F-FDG
PET/CT are needed to enhance their broad application in daily clinical routine.
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